Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial

Video

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Related Videos
Scott T. Tagawa, MD, MS, FACP, FASCO
Jason Efstathiou, MD, DPhil
Daniel Petrylak, MD
Bernard H. Bochner, MD, FACS
Nikhil A. Gopal, MD
Daniel Petrylak, MD
Daniel Petrylak, MD
Matthew Galsky, MD, professor of medicine, Hematology and Medical Oncology, director, Genitourinary Medical Oncology, codirector, Center of Excellence for Bladder Cancer, associate director, Translational Research, The Tisch Cancer Institute of Mount Sinai
Jason Efstathiou, MD, DPhil
Chandler H. Park, MD, FACP
Related Content
Vikram Narayan, MD

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Thomas Powles, MD, MBBS, MRCP

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

April 16th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
Colin PN Dinney, MD

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

April 12th 2024
Article